<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9658">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731666</url>
  </required_header>
  <id_info>
    <org_study_id>US001SU</org_study_id>
    <nct_id>NCT00731666</nct_id>
  </id_info>
  <brief_title>Evaluation of the Coloplast Titan® IPP for Maintaining Penile Length While Treating Erectile Dysfunction (ED)</brief_title>
  <official_title>Prospective, Non-randomized, Multi-center Clinical Trial to Assess the Effectiveness of the Coloplast Titan® IPP at Maintaining or Increasing Penile Length After Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the effectiveness of the Coloplast Titan® Inflatable Penile
      Prosthesis (IPP) at maintaining or increasing penile length after implantation of the
      device. It will incorporate a modified method of cylinder sizing during implantation and a
      max-inflate technique after implantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Study's Primary Objective Will Assess the Change in Penile Length.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Participant Satisfaction With the Penile Length at Baseline, 12 and 24 Months Post Implantation Via Participant Questionaire.</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rate of Change in Male Stress Urinary Incontinence(SUI).</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject responses to 3 questions were evaluated:
On average, how many of these (pads, tissues, disposable undergarments) would you use to protect against wetness during the day?
Overall, how often have you needed to change your daily activities because of urinary incontinence?
Overall, how big of a social problem has urinary incontinence been for you during the past month?</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Titan® IPP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects implanted with Titan® IPP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Inflatable Penile Prosthesis</intervention_name>
    <description>Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.</description>
    <arm_group_label>Titan® IPP</arm_group_label>
    <other_name>Titan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has an estimated life expectancy of more than 5 years

          -  Has been diagnosed with erectile dysfunction

          -  Is willing to have the Titan IPP implanted

          -  Is able and willing to complete all follow-up visits and procedures indicated in this
             protocol

          -  Has been informed of the nature of the study and agrees to its provisions and - Has
             provided written informed consent as approved by the Institutional Review board of
             the respective site

        Exclusion Criteria:

          -  Participant has had a previous penile prosthesis or prior penile enlargement
             surgeries

          -  Participant has a compromised immune system

          -  Participant has had a myocardial infarction or coronary artery stent placement within
             2 months prior to treatment

          -  Participant does not have manual dexterity or mental ability to operate the pump

          -  Participant has an active urogenital infection or active skin infection in region of
             surgery

          -  Participant is diagnosed with fibrotic disease, such as priapism or Peyronie's
             disease

          -  Participant is diagnosed with Chordee

          -  Participant has neuropathy

          -  Participant has a serious bleeding disorder or coagulopathy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Henry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Urology, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Carrion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JAames A Haley VA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Run Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James A Haley VA</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 27, 2013</lastchanged_date>
  <firstreceived_date>August 7, 2008</firstreceived_date>
  <firstreceived_results_date>September 27, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>penile length</keyword>
  <keyword>IPP</keyword>
  <keyword>Erectile dysfunction</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Titan® IPP</title>
          <description>Subjects implanted with Titan® IPP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Titan® IPP</title>
          <description>Subjects implanted with Titan® IPP</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="66.2" spread="11.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Study's Primary Objective Will Assess the Change in Penile Length.</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Titan® IPP</title>
            <description>Subjects implanted with Titan® IPP</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Study's Primary Objective Will Assess the Change in Penile Length.</title>
            <units>cm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pubic bone to meatus - erect</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.14" spread="1.94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubic bone to meatus - flaccid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.99" spread="1.64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubic bone to meatus - stretched</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.04" spread="1.94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubic bone to proximal end of corona - erect</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.94" spread="1.41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubic bone to proximal end of corona - flaccid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.69" spread="1.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubic bone to proximal end of corona - stretched</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.59" spread="1.59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubopenile skin junction to meatus - erect</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.93" spread="1.41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubopenile skin junction to meatus - flaccid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.71" spread="1.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubopenile skin junction to meatus - stretched</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.95" spread="1.98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubopenile skin junct to prox end of corona-erect</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.93" spread="1.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubopenile skin junct to prox end of corona-flacci</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.75" spread="1.58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pubopenile skin junct to prox end of corona-stretc</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.64" spread="2.00"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Participant Satisfaction With the Penile Length at Baseline, 12 and 24 Months Post Implantation Via Participant Questionaire.</title>
        <time_frame>12 and 24 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects implanted with Titan IPP</population>
        <group_list>
          <group group_id="O1">
            <title>Titan® IPP</title>
            <description>Subjects implanted with Titan® IPP</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assess Participant Satisfaction With the Penile Length at Baseline, 12 and 24 Months Post Implantation Via Participant Questionaire.</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>At 12 mo: Over past 4 wks, completely satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At 12 mo: Over past 4 wks, mostly satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At 12 mo: Over past 4 weeks, somewhat dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At 12 mo: Over past 4 wks, completely dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At 24 mo: Over past 4 wks, completely satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At 24 mo: Over past 4 wks, mostly satisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At 24 mo: Neutral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At 24 mo: Over past 4 weeks, somewhat dissatisfied</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At 24 mo: Over past 4 weeks, completely dissatisfi</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Change in Male Stress Urinary Incontinence(SUI).</title>
        <description>Subject responses to 3 questions were evaluated:
On average, how many of these (pads, tissues, disposable undergarments) would you use to protect against wetness during the day?
Overall, how often have you needed to change your daily activities because of urinary incontinence?
Overall, how big of a social problem has urinary incontinence been for you during the past month?</description>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Titan® IPP</title>
            <description>Subjects implanted with Titan® IPP</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Rate of Change in Male Stress Urinary Incontinence(SUI).</title>
            <description>Subject responses to 3 questions were evaluated:
On average, how many of these (pads, tissues, disposable undergarments) would you use to protect against wetness during the day?
Overall, how often have you needed to change your daily activities because of urinary incontinence?
Overall, how big of a social problem has urinary incontinence been for you during the past month?</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Question 1: Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Question 1: Unchanged (Satisfactory)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Question 1: Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Question 2: Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Question 2: Unchanged (Satisfactory)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Question 2: Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Question 3: Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Question 3: Unchanged (Satisfactory)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Question 3: Unchanged (Unsatisfactory)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Question 3: Worsened</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 24 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Titan® IPP</title>
          <description>Subjects implanted with Titan® IPP</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Procedure-related infection.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Manager</name_or_title>
      <organization>Coloplast Corp</organization>
      <phone>612-302-4990</phone>
      <email>usdibe@coloplast.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
